Mucormycosis is a rare fungal infection that threatens the life of especially immunocompromised patients and its treatment is difficult due to diagnostic complexity and limited therapeutic options.[1] A retrospective cohort study from the University Hospital of Liège analyzed 21 cases of mucormycosis diagnosed between July 2018 and August 2023.[1] Pulmonary involvement occurred in 94% of cases, and immunocompromised conditions were identified as the most common risk factors.[1] Liposomal amphotericin B was the most commonly used antifungal treatment, and surgical intervention improved outcomes in 50% of cases where it was performed.[1] Despite these treatment measures, mortality remained significant at 35% at day 84 of follow-up.[1] The high death rate highlights the critical importance of early diagnosis, individualized antifungal therapy, and standardized treatment protocols to improve the chances of survival of patients with this serious infection.[1]